Skip to Main Content

Paper Details

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Nature
105
2021
B.1.351, COVID-19, COVID-191-4, IgG, IgG antibodies, IgG-14, IgM, IgM-14, P, P.1, SARS, SARS-CoV, SARS-CoV-2, concern-B.1.1, engineered IgM, epitope, immunoglobulin G, immunoglobulin M, mice, parental IgG-14
Author NameAffiliation
Xuping XieUniversity of Texas Medical Branch
Vineet D MenacheryUniversity of Texas Medical Branch
Hang SuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Pei-Yong ShiUniversity of Texas Medical Branch
Pei-Yong ShiInstitute for Human Infection and Immunity, University of Texas Medical Branch
Pei-Yong ShiSealy Institute for Vaccine Sciences, University of Texas Medical Branch
Pei-Yong ShiSealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch
Pei-Yong ShiUniversity of Texas Medical Branch
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
  • 1 - 10

Datasets